AstraZeneca (LSE:AZN) has won US Food and Drug Administration approval for Etcamah (camizestrant), in combination with a CDK4/6 inhibitor, to treat adults with hormone receptor (HR)-positive, HER2-negative advanced breast cancer.
The approval covers patients who develop an ESR1 gene mutation while on first-line aromatase inhibitor and CDK4/6 inhibitor therapy, detected via an FDA-authorised test.
The accelerated approval rests on the Phase III SERENA-6 trial, which showed the Etcamah combination cut the risk of disease progression or death by 56% against standard-of-care treatment, with median progression-free survival of 16.0 months versus 9.2 months.
A pre-planned follow-up analysis also showed a statistically significant benefit on time to second disease progression, at 25.7 months versus 19.1 months, while overall survival data continued to mature in the drug's favour.
"This combination provides an important new option for the one in three patients with this form of advanced breast cancer whose tumours develop ESR1 mutations before clinical or radiographic disease progression," said Kevin Kalinsky, an investigator on the trial and division director at Winship Cancer Institute of Emory University.
Dave Fredrickson, AstraZeneca's oncology haematology business unit head, noted this is the tenth FDA approval across the company's portfolio this year, and its fourth in breast cancer alone.
The regulator simultaneously approved a companion diagnostic to detect emerging ESR1 mutations via a blood-based circulating tumour DNA test, the first such ctDNA-guided approach used in a registrational Phase III breast cancer trial.
Etcamah is now approved in more than 30 countries, including the EU, Japan, Canada and the UK.
News Intelligence what this means for the company
AstraZeneca won FDA accelerated approval for Etcamah (camizestrant) plus a CDK4/6 inhibitor in HR-positive breast cancer patients with ESR1 mutations acquired on first-line therapy. The Phase III SERENA-6 trial showed a 56% reduction in progression or death risk, with median PFS of 16.0 months versus 9.2 months for standard care, and a statistically significant benefit on time to second progression (25.7 vs 19.1 months). This is AstraZeneca's fourth breast cancer approval this year and expands Etcamah's footprint to over 30 countries.
The approval validates Etcamah's clinical profile in a defined, treatment-resistant population (one in three HR-positive patients develop ESR1 mutations on first-line therapy) and marks the first registrational Phase III breast cancer trial to use a blood-based ctDNA companion diagnostic, potentially setting a template for future oncology development. However, the accelerated pathway and ongoing overall survival maturation mean full commercial impact remains contingent on final OS data and reimbursement decisions.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
